Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study - 27/08/14
, Peter L Anderson, ProfPharmD d, Vanessa McMahan, BSc a, Albert Liu, MD b, e, K Rivet Amico, PhD f, Megha Mehrotra, MPH a, Sybil Hosek, PhD g, Carlos Mosquera, MD h, Martin Casapia, MD i, Orlando Montoya j, Susan Buchbinder, MD b, e, Valdilea G Veloso, MD k, Kenneth Mayer, ProfMD l, Suwat Chariyalertsak, ProfMD m, Linda-Gail Bekker, ProfPhD n, Esper G Kallas, MD o, Mauro Schechter, ProfMD p, Juan Guanira, MD h, Lane Bushman, BChem d, David N Burns, MD q, James F Rooney, MD r, David V Glidden, ProfPhD bfor the iPrEx study team
Summary |
Background |
The effect of HIV pre-exposure prophylaxis (PrEP) depends on uptake, adherence, and sexual practices. We aimed to assess these factors in a cohort of HIV-negative people at risk of infection.
Methods |
In our cohort study, men and transgender women who have sex with men previously enrolled in PrEP trials (ATN 082, iPrEx, and US Safety Study) were enrolled in a 72 week open-label extension. We measured drug concentrations in plasma and dried blood spots in seroconverters and a random sample of seronegative participants. We assessed PrEP uptake, adherence, sexual practices, and HIV incidence. Statistical methods included Poisson models, comparison of proportions, and generalised estimating equations.
Findings |
We enrolled 1603 HIV-negative people, of whom 1225 (76%) received PrEP. Uptake was higher among those reporting condomless receptive anal intercourse (416/519 [81%] vs 809/1084 [75%], p=0·003) and having serological evidence of herpes (612/791 [77%] vs 613/812 [75%] p=0·03). Of those receiving PrEP, HIV incidence was 1·8 infections per 100 person-years, compared with 2·6 infections per 100 person-years in those who concurrently did not choose PrEP (HR 0·51, 95% CI 0·26–1·01, adjusted for sexual behaviours), and 3·9 infections per 100 person-years in the placebo group of the previous randomised phase (HR 0·49, 95% CI 0·31–0·77). Among those receiving PrEP, HIV incidence was 4·7 infections per 100 person-years if drug was not detected in dried blood spots, 2·3 infections per 100 person-years if drug concentrations suggested use of fewer than two tablets per week, 0·6 per 100 person-years for use of two to three tablets per week, and 0·0 per 100 person-years for use of four or more tablets per week (p<0·0001). PrEP drug concentrations were higher among people of older age, with more schooling, who reported non-condom receptive anal intercourse, who had more sexual partners, and who had a history of syphilis or herpes.
Interpretation |
PrEP uptake was high when made available free of charge by experienced providers. The effect of PrEP is increased by greater uptake and adherence during periods of higher risk. Drug concentrations in dried blood spots are strongly correlated with protective benefit.
Funding |
US National Institutes of Health.
Le texte complet de cet article est disponible en PDF.Plan
Vol 14 - N° 9
P. 820-829 - septembre 2014 Retour au numéro
Article précédent
- Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study
- Rodrigo Lopez Castelblanco, MinJae Lee, Rodrigo Hasbun
- Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study
- Jorge E Osorio, Ivan D Velez, Cynthia Thomson, Liliana Lopez, Alejandra Jimenez, Aurelia A Haller, Shawn Silengo, Jaclyn Scott, Karen L Boroughs, Janae L Stovall, Betty E Luy, John Arguello, Mark E Beatty, Joseph Santangelo, Gilad S Gordon, Claire Y-H Huang, Dan T Stinchcomb
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?